Alzheimer's

Japan’s health ministry has approved Leqembi, a drug for Alzheimer’s decease that was jointly developed by Japanese and U.S. pharmaceutical companies.

Latinos are 1.5 times more likely to develop Alzheimer’s than other races, according to the Alzheimer’s Association.

The Alzheimer’s Association created a list of early signs of the disease or other types of dementia. In the United States, the disease disproportionately affects Hispanic patients.

Barker died at age 99 from Alzheimer’s disease and other contributing factors, as outlined in his death certificate.

Some private insurers are balking at paying for the first drug fully approved to slow mental decline in Alzheimer’s patients.

If U.S. regulators approve, the drug would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease — after rival Leqembi. Both drugs pose a serious safety concern — brain swelling and bleeding.

Leqembi slowed cognitive decline in a clinical trial, but the treatment is expensive and carries serious risks of brain swelling and bleeding.

U.S. health advisers are backing the full approval of an Alzheimer’s drug that received preliminary approval last year. A panel of advisers to the Food and Drug Administration on Friday voted in favor of the infused medication from drugmakers Eisai and Biogen. The FDA granted accelerated approval in January based on early results suggesting the drug could modestly slow Alzheimer’s....

Patients will have to participate in registries that collect real-world data on how the drug works as a condition of coverage.

Eli Lilly and Co. said Wednesday its experimental Alzheimer’s drug appeared to slow worsening of the mind-robbing disease in a large study. NBC 5’s Bianca Castro talked with Frisco neurologist Dr. Aimee Garza about how it works.

Eli Lilly and Co. says its experimental Alzheimer’s drug appears to slow worsening of the mind-robbing disease after an 18-month trial.

Medicare has severely restricted access to the medication Leqembi, which costs $26,500 per year, because the FDA approved it just on an expedited basis.

Eli Lilly said a higher dose of the up-and-coming Alzheimer’s treatment remternetug had a larger effect on clearing amyloid plaque.

Scientists are digging into why a few people escape the rarest form of Alzheimer’s, which is inherited and strikes young. Every so often, someone dodges their family’s genetic fate.

The first drug to show that it slows Alzheimer’s is on sale, but treatment for most patients is still several months away. Experts say scant coverage of the drug and a long setup time needed by health systems are two main factors behind the slow debut. The U.S. Food and Drug Administration approved Leqembi from Japanese drugmaker Eisai in early...

A new Alzheimer’s drug is hitting the market with experts voicing a lot of caution.

The Biogen company wanted to set an “unjustifiably high” initial price of $56,000 a year for the Alzheimer’s drug, investigators said.

Biogen and Japan’s Eisai Co. said early results showed that the treatment, lecanemab, reduced patient clinical decline by 27% when compared to a placebo after 18 months of the infused treatment

New research hints that even simple exercise just might help seniors with mild memory problems.